Published in final edited form as:

Cancer Res. 2007 August 1; 67(15): 7450–7457. doi:10.1158/0008-5472.CAN-07-0199.

Targeting Human $\gamma\delta$ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer

Francesco Dieli¹, David Vermijlen³, Fabio Fulfaro², Nadia Caccamo¹, Serena Meraviglia¹, Giuseppe Cicero², Andrew Roberts³, Simona Buccheri¹, Matilde D'Asaro¹, Nicola Gebbia², Alfredo Salerno¹, Matthias Eberl^{4,5}, and Adrian C. Hayday³

¹Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Palermo, Italy

²Section of Medical Oncology, Dipartimento di Chirurgia ed Oncologia, Università di Palermo, Palermo, Italy

³Peter Gorer Department of Immunobiology, The Medical School of King's College at Guy's and St. Thomas' Hospitals, London, United Kingdom

⁴Institute of Cell Biology, University of Bern, Bern, Switzerland

⁵Department of Medical Biochemistry and Immunology, Cardiff University School of Medicine, Cardiff, United Kingdom

Introduction

Prostate cancer is the most common cancer diagnosis and the second leading cause of cancer-related deaths in men (1). Although 10-year cancer-specific survival rates are ~95% to 97% for radically prostatectomized patients with localized prostate cancer, up to one third such individuals experience disease recurrence (2, 3). In a median of 8 years after relapse, these patients will suffer from metastatic disease leading to death within another 2 to 5 years, independently of the applied treatment regimen (4). Advanced, recurrent, and metastatic tumors treated by androgen deprivation convert to androgen-independent growth within a few years and patients with metastatic hormone-refractory prostate cancer (HRPC) have a median survival of only 16 months. Treatment options are limited to aggressive chemotherapy with survival benefits of 2 to 3 months (5, 6). This lack of effective therapies for HRPC has fueled an intensive search for novel modalities, including immunotherapy (5–8).

There is good evidence that tumors can naturally be controlled by the immune system (9), and most immunotherapy strategies aim to induce adaptive, tumor-specific responses of B cells and MHC-restricted $\alpha\beta$ T cells, particularly CD8 T cells. Nonetheless, despite major advances in this area, and the introduction of vaccine-based strategies, durable responses are rare and active immunotherapy is not yet an established modality. Tumor immunoevasion mechanisms are common and include the down-regulation of tumor-associated antigens, of MHC, and of costimulatory molecules (9, 10). By contrast to $\alpha\beta$ T cells, $\gamma\delta$ T cells are not MHC restricted and show less dependence on costimulators such as CD28. Moreover, $\gamma\delta$ T cells are a natural component of resistance to cutaneous carcinogenesis in mice (11), and in humans display potent MHC-unrestricted cytotoxic activity *in vitro* against various tumors, including prostate cancer cell lines (12, 13). Indeed, human V γ 9V δ 2 T cells expanded *ex vivo* and then adoptively transferred to severe combined immunodeficient mice xenografted with tumor cells showed efficacy against B-cell lymphoma; melanoma; and renal, pancreatic, and nasopharyngeal carcinoma (14). Building on this, the potential of human $\gamma\delta$

T cells for tumor immunotherapy has been directly analyzed and was recently expertly reviewed (15, 16).

Among $\gamma\delta$ T cells, human peripheral blood V γ 9V δ 2 T cells recognize low molecular mass nonpeptide ligands (17–20). Such “phosphoantigens” comprise isoprenoid pathway metabolites, as (*E*)-4-hydroxy-3-methyl-but-2-enyl PPi (HMB-PP) derived from bacteria and protozoa (19) and isopentenyl PPi (IPP) derived from host cells (20). Accordingly, pharmacologic agents, such as aminobisphosphonates, that cause an accumulation of such metabolites (21), sensitize tumor cells to V γ 9V δ 2 T cells. Recognition may then be sustained by the tumor cell expression of NKG2D ligands, such as MICA and MICB, and of an ATPase that binds the V γ 9V δ 2 T-cell receptor (TCR; ref. 22), and that unlike in normal cells is ectopically expressed on the tumor cell surface.

Like other T cells, V γ 9V δ 2 lymphocytes comprise distinct populations distinguishable on the basis of surface markers, effector functions, and trafficking properties. Naïve (T_{naïve}, CD45RA+CD27+) and central memory (T_{CM}, CD45RA–CD27+) cells home to secondary lymphoid organs and lack immediate effector functions, whereas the so-called effector-memory (T_{EM}, CD45RA–CD27–) and terminally differentiated (T_{EMRA}, CD45RA+CD27–) cells home to sites of inflammation where they display immediate effector functions such as cytokine production and cytotoxicity (23). Such functions are attractive weapons for immunotherapy strategies, and there are promising results from recent, relatively small-scale applications of V γ 9V δ 2 T cells to hematologic (24) and solid-tissue malignancies, including prostate cancer (25) and advanced renal cell carcinoma (26). Assessing that aminobisphosphonates such as zoledronate are already widely used in the clinic, we have conducted a phase I clinical trial in metastatic HRPC to determine the safety, feasibility, and response induced by activating V γ 9V δ 2 T cells *in vivo* using zoledronate either alone or in combination with low-dose IL-2. Although there has been a promising application of pamidronate and IL-2 to prescreened multiple myeloma and non-Hodgkin’s lymphoma patients (24), there has been only one reported, small-scale application of zoledronate to solid tumors (25), and the consequences of a selective activation of $\gamma\delta$ T cells *in vivo* were unknown before the current study. In this regard, data presented here support the proposal that zoledronate + IL-2 may prove a novel, safe, feasible, and efficacious means to extend the life span of those with late stage metastatic carcinoma, and thereby to increase the window of the patients’ availability for other, more tumor-specific molecular approaches.

Materials and Methods

Study design

Treatment of patients according to an institutional review board–approved protocol was done following written informed consent from each subject or subject’s guardian. The study was designed only for metastatic HRPC, and 18 patients [age range 61–78 years (median 68 years)] pretreated with androgen deprivation and radiotherapy and/or chemotherapy were enrolled. Only patients with an expected life span of ~3 months, with the presence of bone metastasis and a Kernovsky index >60%, were included. All patients had a prostate-specific antigen (PSA) increase of 20% within 2 months. The median pretreatment PSA doubling time, calculated as described in ref. (27) was 4.1 months (range 4.3–3.9 months, respectively), and the median time to progression was 10.6 months (95% CI, 7.8–13.2 months). No statistically significant difference in either PSA doubling time or time to progression was found between patients enrolled to receive zoledronate and zoledronate + IL-2. With the exception of patients 1B and 2B, all other patients received docetaxel 36 mg/m² i.v. over 15 to 30 min weekly for 6 consecutive weeks, on an 8-week cycle. All the patients had received four to five cycles docetaxel before being enrolled in this study.

Patients were excluded if they were receiving any chemotherapy, radiation therapy, or bisphosphonates over a period 6 weeks before study entry; if they had severe cardiovascular disease, refractory hypertension, symptomatic coronary artery disease; a serum creatinine of >3.0 mg/dL or a corrected (for albumin) serum calcium of <8.0 mg/dL; if they had CNS metastases; a history of autoimmunity, with serious intercurrent chronic or acute illnesses or concurrent second malignancy; or if they were being treated with steroids or other immunosuppressive agents. Treatment with antiandrogen was withdrawn at least 4 weeks before study entry, whereas continuation of gonadal androgen suppression was conducted on all patients on luteinizing hormone-releasing hormone analogues. The main characteristics of the patients are shown in Supplementary Table S1. The clinical status of patients was evaluated according to Response Evaluation Criteria in Solid Tumors (28).

Treatment schedule

Eighteen subjects with metastatic HRPC were enrolled and randomized to receive either zoledronate (cohort A) or zoledronate + IL-2 (cohort B). Zoledronate (Novartis) was administered by a 15 min 100 mL i.v. infusion of normal saline at a standard dose of 4 mg, every 21 days. IL-2 (Chiron, 0.6×10^6 IU) was administered s.c. immediately after each zoledronate administration. All patients received 500 mg calcium supplement and 400 IU of vitamin D daily. This treatment schedule was done for 1 year.

Flow cytometry

Patients' blood samples were collected before (month 0) and at 3 months (6 days after the fourth administration of zoledronate or zoledronate/IL-2), 9 months (6 days after the 13th administration of zoledronate or zoledronate/IL-2), and 12 months (6 days after the 17th administration of zoledronate or zoledronate/IL-2) after the study began. Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll-Hypaque centrifugation and stained with FITC-, phycoerythrin-, phycoerythrin-Cy5-, or allophycocyanin-conjugated antibodies against CD27, CD45RA, CD69, HLA-DR, CD3, CD56, CD4, CD8, TCR pan $\alpha\beta$, TCR pan $\gamma\delta$, TCR V γ 9, or TCR V δ 2 [all monoclonal antibodies (mAb) were from BD PharMingen]. Cells (10^5) from each sample were analyzed using a FACScalibur supported with CellQuest acquisition and data analysis software (Becton Dickinson). The lymphocytes were gated for forward/side scatter.

Analysis of V γ 9V δ 2 T cells

The medium used throughout was complete RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated human pooled AB serum, 2 mmol/L L-glutamine, 20 nmol/L HEPES, and 100 units/mL penicillin/streptomycin. PBMC were labeled with CFSE (Molecular Probes) and cultured at 37°C, in 5% CO₂, at 10⁶/mL in 96-well flat-bottomed plates (0.2 mL/well), with isopentenyl PPi (IPP, Sigma Chemical Co.; 10⁻⁵ mol/L final concentration) and 20 units/mL IL-2 (23, 25). Seven days later, cells were collected and the percentage of V γ 9V δ 2 cells within the CD3+ population was assessed by fluorescence-activated cell sorting (FACS). The absolute number of V γ 9V δ 2 T cells present in each culture was calculated according to the following formula: % V γ 9V δ 2 T cells $\times$ total number of viable cells/100. The V γ 9V δ 2 T-cell expansion factor was then calculated by dividing the absolute number of V γ 9V δ 2 T cells in stimulated cultures by the number of V γ 9V δ 2 T cells cultured in the absence of IPP (23). IFN γ levels in the 48 h culture supernatants were assessed by two mAbs sandwich ELISA (23) following manufacturer's recommendations (R&D Systems). Na-CBZ-L-lysine-thiobenzyl (BLT)-esterase levels in 24 h culture supernatants were determined by the BLT esterase assay. Briefly, 20 μ L culture supernatant were incubated with 35 μ L 1 mmol/L BLT (Sigma), 35 μ L 1 mmol/L 5-5'-dithio-bis-(2-nitrobenzoic acid; Sigma), and 10 μ L 0.1% Triton X-100 (Sigma). After incubation for 30 min at 37°C, absorbance was measured at 405 nm (23).

Intracellular staining for IFN- γ and perforin

PBMC stimulated with IPP as described above, in the presence of monensin for 6 h at 37°C in 5% CO₂ were harvested, washed, and stained with anti-V δ 2 mAb in incubation buffer (PBS containing 1% FCS and 0.1% Na azide) for 30 min at 4°C. Cells were then washed twice in PBS with 1% FCS and fixed with PBS containing 4% paraformaldehyde overnight at 4°C. Fixation was followed by permeabilization with PBS containing 1% FCS, 0.3% saponin, and 0.1% Na azide for 15 min at 4°C, and fixed permeabilized cells were stained with an anti-IFN- γ antibody. After two more washes in PBS containing 1% FCS, the cells were analyzed by FACSCalibur. Lymphocytes were gated by forward and side scatter and analysis done on 100,000 acquired events for each sample. For detection of intracellular perforin, PBMC were stained directly *ex vivo* (i.e., without any antigen stimulation *in vitro*) in calcium-free medium with anti-V δ 2 mAb as above described, washed, and fixed with PBS containing 4% paraformaldehyde for 30 min at 4°C. After two washes in permeabilization buffer, cells were stained with antiperforin antibody (δ G2, Alexis; 2 μ g/mL); after two more washes in PBS + 1% FCS, the cells were analyzed as above.

Analysis of tumor necrosis factor–related apoptosis inducing ligand expression

PBMC from healthy volunteers were stimulated *in vitro* for 3 days with zoledronate at the indicated concentrations, with or without IL-2 (100 units/mL). Brefeldin A (Sigma) was added to the cultures at 10 μ g/mL 3 h before harvest, and surface-stained cells (CD3-ECD and V γ 9-PE-Cy5, Beckman Coulter) were then labeled using the Fix & Perm kit (Caltag) with anti-TRAIL (tumor necrosis factor–related apoptosis inducing ligand)-phycoerythrin (BD Biosciences). TRAIL in sera was detected using a human TRAIL DuoSet ELISA kit (R&D Systems).

Statistical analysis

Kaplan-Meier curves were used to assess the effect of treatments on 12-month survival; a sample size calculation of 18 patients (nine per group) assured a power of 85% in detecting a 3-month difference in survival curves among groups, with a SD of ± 3 and a two-sided α error of 5. The significance of the differences in survival was assessed using the log-rank, Breslow (Generalized Wilcoxon), or Tarone-Ware tests. Data from more than two groups were compared using one-way ANOVA with Tukey-Kramer multiple comparison test using Instat software (version 3.05, GraphPad). *P* values <0.05 were considered statistically significant.

Results

Rationale

Human V γ 9V δ 2 T cells can be activated in a non-MHC–dependent manner by phosphoantigens or by agents that provoke the accumulation of endogenous PPI such as IPP. Among such agents, aminobisphosphonates are already widely used in the clinic, for example, to diminish osteoclast activity in osteoporosis or in elderly patients receiving chronic steroid treatment. By several criteria, zoledronate is the most potent and efficacious clinically approved aminobisphosphonate (29, 30). Our ongoing molecular analyses of V γ 9V δ 2 T-cell responses have indicated that IL-2 up-regulates several effector molecules that may be efficacious in tumor therapy, and is active *in vivo* on V γ 9V δ 2 T cells at a lower concentration than that required to affect $\alpha\beta$ T cells or natural killer (NK) cells. For these reasons, we rationalized that zoledronate $\pm$ low-dose IL-2 may provide a feasible and safe means to activate V γ 9V δ 2 T cells *in vivo*.

Toxicity

One to 3 days after the first administration, six of nine patients treated with zoledronate + IL-2 (67%) and two of nine patients treated with zoledronate alone (22%) developed a transient flu-like syndrome that was easily controlled by oral paracetamol. This side effects was expected as it was also detected after application of pamidronate and IL-2 to multiple myeloma and non-Hodgkin's lymphoma patients (24). Two patients (22%) receiving zoledronate + IL-2 developed a local erythema at the site of IL-2 administration. No other hematologic, hepatic, renal, or neurologic toxicity, or allergic, autoimmune, or fatigue side effect was observed during the treatment.

$\gamma\delta$ T-cell responses

Phenotypic and functional responses of $\gamma\delta$ T cells were measured before and at 3, 9, and 12 months after beginning treatment with zoledronate $\pm$ IL-2 (Fig. 1A and B). By multiple criteria, the surviving patients in the two treatment protocols showed substantially different effects on $\gamma\delta$ cells. Before treatment, almost all patients displayed $\sim 25 \times 10^3$ to 45×10^3 $\gamma\delta$ cells per milliliter of blood. As four patients treated with zoledronate alone (cohort A) died before month 3, longitudinal analysis was possible in only five such patients (1A, 2A, 3A, 7A, and 8A). Of these, only patient 7A sustained starting levels of $\gamma\delta$ cells across the treatment period. Although patient 1A showed a transient increase in $\gamma\delta$ cell numbers at 3 months, the cells then declined to below starting levels.

In stark contrast, seven patients treated with zoledronate + IL-2 (cohort B) survived past month 12, of whom five (1B, 2B, 3B, 4B, and 8B) showed sustained or increased numbers of peripheral $\gamma\delta$ T cells across the full period. One surviving patient (9B) showed a decrease in peripheral $\gamma\delta$ T cells, up to 9 months, although those numbers then stabilized, whereas another (6B) showed a more substantial ongoing decline. Both of the two cohort B patients who died (5B and 7B) displayed precipitous and progressive decreases in peripheral blood $\gamma\delta$ T-cell numbers. In addition to the different frequencies of peripheral blood $\gamma\delta$ cells in the two cohorts, there was a more pronounced increase in CD69 (Fig. 1C) and/or HLA-DR (Fig. 1D) antigens on $\gamma\delta$ T cells in cohort B, indicating greater activation *in vivo*. The stimulatory effects of zoledronate $\pm$ IL-2 treatment were largely restricted to $\gamma\delta$ T cells, because neither absolute numbers nor CD69 and HLA-DR expression were altered on $\alpha\beta$ T cells or NK cells (Supplementary Table S2).

When a subset analysis was done on $\gamma\delta$ T cells in the seven cohort B patients surviving through month 12, there were in all cases sharp and progressive decreases in absolute numbers of cells with naïve-like and central memory-like phenotypes ($T_{naïve}$ and T_{CM} $\gamma\delta$ T cells), and, correspondingly, albeit more variable increases in cells with effector memory-like and terminally differentiated phenotypes (T_{EM} and T_{EMRA} $\gamma\delta$ cells), although the T_{EMRA} $\gamma\delta$ cells declined somewhat by 12 months (Fig. 2). The pattern of increased numbers and an altered phenotype of peripheral $\gamma\delta$ cells was strikingly depicted by the raw data for patient 1B shown in Supplementary Fig. S1. Overall, the statistically significant changes indicate that zoledronate + IL-2 provokes a long-term effector maturation and mobilization of peripheral blood $\gamma\delta$ T cells and evoke our previous observations after zoledronate injection in cancer patients (25). Indeed, a similar trend was seen in the three patients treated with zoledronate alone surviving more than 12 months (data not shown), although the absolute numbers of peripheral $\gamma\delta$ T cells declined in all but one of these patients (7A).

The phenotypic modifications of $\gamma\delta$ T cells in cohort B were paralleled by modifications in functional responses *in vitro*. As shown in Fig. 3 , proliferative responses to IPP declined over time, whereas the capacity to produce IFN- γ and to release BLT-esterase (as a variable

of cytotoxicity) consistently increased, peaking at 9 months. Again, this trend is illustrated by raw data for patient 1B (Supplementary Fig. S2).

Clinical responses and clinical correlates

Only two of nine patients treated with zoledronate alone showed any clinical response (Supplementary Table S1, Fig. 1A). In one patient (1A), stable disease was observed over 14 months, whereas patient 7A, who was the only patient in cohort A to sustain pretreatment levels of $\gamma\delta$ T cells, achieved a partial remission. In contrast, six of nine patients treated with zoledronate + IL-2 showed favorable clinical responses (Supplementary Table S1; Fig. 1B). Two patients (1B and 8B) achieved a partial remission, and each showed aggregate increases in $\gamma\delta$ T-cell numbers across the treatment period. Four additional patients (2B, 3B, 4B, and 9B) achieved stable disease, lasting 14 to 16 months, and with a sole exception (9B) each showed sustained $\gamma\delta$ T-cell numbers; indeed, even in 9B, $\gamma\delta$ T-cell numbers had stabilized by 9 to 12 months at $\sim 10 \times 10^3$ $\gamma\delta$ T cells per milliliter of blood. By contrast, the deterioration of patients 5B, 6B, and 7B was in each case preceded by a substantial decline in $\gamma\delta$ T-cell numbers (Fig. 1A and B). The 12-month survival curves of patients treated with zoledronate alone and those treated with zoledronate + IL-2 is shown in Fig. 4A. Figure 4B shows echo-color Doppler imaging of the prostate of patient 1B before (*top*) and 12 months (*bottom*) after zoledronate + IL-2 therapy, showing regression of prostate malignancy.

The *prima facie* correlation between 12-month clinical outcome (i.e., partial remission versus stable disease versus progression) and, respectively, increases in, maintenance of, or decreases in circulating $\gamma\delta$ T-cell numbers was provocative and was investigated further. A statistically significant correlation existed between favorable outcome at 12 months, and either total $\gamma\delta$ cell numbers or the numbers of TCR $\gamma\delta$ T_{EM} cells measured at 9 months (Fig. 5A and B). Moreover, a statistically significant inverse correlation was also found between either total $\gamma\delta$ T cells or TCR $\gamma\delta$ T_{EM} cells and serum PSA levels at 9 months (Fig. 5C and D). Of note, we did not find any correlation between pretreatment PSA levels and total $\gamma\delta$ cells ($r = 0.0033$, $P = 0.99$) or their T_{EM} subset ($r = 0.088$, $P = 0.81$). To illustrate this point further, Supplementary Fig. S3A and B shows a longitudinal analysis of total $\gamma\delta$ cells, the $\gamma\delta$ T_{EM} subset, and serum PSA levels in a patient (1B) achieving an objective immune response (partial remission), and in a patient (6B) showing disease progression.

The highly distinct clinical outcomes in the two cohorts prompted us to examine further the differences that might exist between them. Related to this, a set of microarray analyses was undertaken while the trial was ongoing, of human peripheral blood $\gamma\delta$ cells stimulated with a phosphoantigen TCR agonist (HMB-PP) in the presence of different cytokines, including IL-2 (31). The study confirmed that IFN- γ and tumor necrosis factor- α are up-regulated in such circumstances, but additionally found that the cytolytic mediator, TRAIL, was specifically up-regulated in the presence of IL-2. We therefore tested whether TRAIL was likewise up-regulated *in vitro* by zoledronate + IL-2, more than by zoledronate alone, and confirmed that it was, identifying a provocative potential difference between the two cohorts (Fig. 6A). Although these findings postdated the analysis of patients' $\gamma\delta$ T cells, an *a posteriori* examination of patients' serum showed that TRAIL levels were essentially maintained in cohort B, whereas they mostly declined in cohort A (Fig. 6B). Of note, the single outlier in cohort A (7A) whose TRAIL levels had recovered close to their pretreatment levels by 9 months was also the one patient treated with zoledronate alone who maintained $\gamma\delta$ T-cell numbers and who showed a partial remission. When serum TRAIL levels at 9 months were examined for all 11 patients surviving at 12 months, there was a clear trend whereby higher TRAIL levels were associated with improved clinical outcome (Fig. 6C); in fact, there was only a single overt outlier (6B) who was treated with zoledronate + IL-2 and who maintained TRAIL levels, but whose disease progressed. This

patient prevented the correlation between TRAIL levels and outcome reaching statistical significance. Nonetheless, the likely biological significance of the correlation between clinical outcome and serum TRAIL concentrations at 9 months was highlighted by the lack of an obvious correlation with other variables, including pretreatment TRAIL levels (Supplementary Fig. S4), and 9-month levels of other immunologic mediators (data not shown).

Discussion

Several observations in mice and in humans have collectively laid the foundation for examining the potential of $\gamma\delta$ T cells to exert tumor immunotherapy. A practical issue has been how to accomplish this. In this regard, an attractive feature of human peripheral blood V γ 9V δ 2 T cells is their capacity to be readily and specifically activated either by low molecular mass phosphoantigens, such as HMB-PP or IPP, or by agents that provoke IPP accumulation. Among the latter, aminobisphosphonates are well established in the clinic, and extensive data are available on the antiangiogenic, antiosteolytic, and proapoptotic properties of the compounds (29, 30).

In patients with multiple myeloma or with low-grade non-Hodgkin lymphoma, occurrences of acute-phase reaction to i.v. pamidronate were attributed to the systemic activation of phosphoantigen-reactive $\gamma\delta$ T cells (24), and this provoked the deliberate treatment of lymphoma patients with pamidronate and low-dose IL-2. This achieved some promising results after patients were prescreened for those whose $\gamma\delta$ T cells would substantively respond to pamidronate + IL-2 *in vitro* (24). By several criteria, zoledronate is more potent and efficacious than pamidronate, and previous studies by our own group in patients with breast ($n = 3$) and prostate ($n = 6$) tumors showed that zoledronate induced *in vivo* the maturation of peripheral blood $\gamma\delta$ T cells into more potent cytotoxic and IFN- γ -secreting cells (25). This notwithstanding, there has hitherto been no study of the consequences of a selective activation of $\gamma\delta$ T cells *in vivo* in patients with late-stage, metastatic carcinomas, a significant unmet clinical need. Moreover, there has been no assessment of the consequences of administering zoledronate *in vivo* in the presence or absence of a specific cytokine, such as IL-2. This is important given the evidence that the differentiation of $\gamma\delta$ cells, like other T cells, is substantially influenced by the prevailing cytokine milieu (31–34). Given such paucity of existing data, the assessment of toxicity was a major aim of the current study. Our findings reveal that the combination of zoledronate + IL-2 was well tolerated, with no long-term overt toxicity observed. Consistent with a lack of significant side effects, neither zoledronate nor IL-2 used at the low doses described in this study had any measurable effects on either $\alpha\beta$ T cells or NK cells (Supplementary Table S2).

A second aim of our study was to assess whether reproducible phenotypic changes were induced in the $\gamma\delta$ T-cell compartment. In this regard, the most striking effect was the long-term and substantial differentiation of $\gamma\delta$ T cells toward an effector-memory-like phenotype, with absolute numbers of such cells particularly enhanced in patients treated with zoledronate + IL-2; indeed, absolute numbers of peripheral T_{naive} and T_{CM} $\gamma\delta$ cells decreased by 3 months after treatment and had virtually disappeared at 9 to 12 months. This was seen in the majority of zoledronate + IL-2-treated patients without any prescreening for those whose cells would respond to this regimen *in vitro*. Based on variable $\gamma\delta$ T-cell repertoires and on the preexisting status of such cells, it is known that peripheral blood responses to phosphoantigens or aminobisphosphonates show individual variation, and by analogy to earlier studies in lymphoma (24), one can only assume that such prior screening may well improve the response rate to zoledronate + IL-2. A similar trend was seen in three of nine patients receiving zoledronate alone, although they were, with one exception (7A),

less impressive, and may have been sustained by individually variable levels of endogenous cytokines.

A third and final aim of our study was to assess whether there was a differential clinical response to the treatment regimens. Indeed, whereas only two of nine patients treated with zoledronate achieved an objective tumor response, this was true for 67% of those treated with zoledronate + IL-2, where the response at 12 months showed a correlation with the absolute numbers of total $\gamma\delta$ T cells; with the numbers of $\gamma\delta$ T_{EM} cells; and although not significantly, with serum levels of TRAIL measured at 9 months posttreatment. Moreover, the fact that clinical outcome was influenced by the type of regimen used to activate $\gamma\delta$ T cells strongly suggests that $\gamma\delta$ T-cell activation is at least partially causal to the response. Thus, $\gamma\delta$ T cells stimulated *in vitro* with zoledronate and IL-2 possess an increased capacity for killing tumor cells *in vitro* (30),⁶ whereas our immunologic monitoring provided no evidence that zoledronate $\pm$ low-dose IL-2 induced activation, expansion, and/or differentiation of either $\alpha\beta$ T cells or NK cells (note that the concentration of IL-2 used here is much lower than that used in other immunotherapies; refs. 35–37). Interestingly, it was recently reported that the presence of T_{EM} cells within colorectal cancer correlates with the absence of pathologic evidence of early metastases and with prolonged survival (38). However, despite the provided *in vitro* evidence that stimulation with zoledronate + IL-2 increases the production of TRAIL by $\gamma\delta$ cells in short-term cultures, we have actually no proof that $\gamma\delta$ cells solely contribute to sustained serum TRAIL levels in patients treated with zoledronate + IL-2. The finding that neither absolute numbers nor CD69 and HLA-DR expression were altered on $\alpha\beta$ T cells or NK cells (Supplementary Table 2) strongly points to a selective effects on $\gamma\delta$ cells. The fact that patients enrolled in this study were at a terminal stage of disease might also contribute to the lack of increase in serum TRAIL levels.

We have yet to elucidate the key contributions to tumor regulation made by $\gamma\delta$ T_{EM} cells induced by zoledronate + IL-2. Nonetheless, clues should exist in the ongoing microarray analysis of V γ 9V δ 2 cells stimulated via the TCR in the presence of IL-2. This study has already provoked our analysis of TRAIL as a potential active component, and, guided by this, future studies will look directly at TRAIL production by $\gamma\delta$ T cells in an immunotherapy context. For several reasons, TRAIL is an attractive candidate: For example, it kills many tumor cell lines but not most nontransformed cells, and the selective efficacy of histone deacetylase inhibitors versus acute myeloid leukemia cells involves TRAIL induction *in vivo* (39, 40). Nonetheless, there is a view that the results using agonistic anti-TRAIL receptor antibody as an antitumor agent have been disappointing, perhaps because of resistance to TRAIL-mediated apoptosis, which is common in cancer cells (41). Interestingly, resistance can be overcome by IFN- γ (42), which is produced in high amounts by zoledronate + IL-2-stimulated V γ 9V δ 2 T cells, and which is positively reinforced by signaling via TRAIL, and vice versa (43, 44). Thus, it is the maintenance of TRAIL production in the context of other products of V γ 9V δ 2 T_{EM} cells that may be key, consistent with which clinical outcome did not correlate with pretreatment levels of TRAIL. This emphasizes a major potential advantage of cell-based therapy. Indeed, the combination of an agonistic anti-TRAIL receptor antibody and the induction of IFN- γ -producing T cells was shown to eradicate established tumors in mice (45).

The encouraging prospect that the activation of peripheral blood V γ 9V δ 2 T cells can be efficacious against solid tumors requires further follow-up, including an analysis of tumor-infiltrating lymphocytes to assess whether the activated cells are indeed infiltrating the tumors and/or are helping other cells to do so. Wang and colleagues recently reported that human prostate and breast carcinoma are naturally and strongly infiltrated by TRAIL-producing $\gamma\delta$ T cells,⁷ suggesting the value of analyzing the regulation on zoledronate +

IL-2–stimulated-V γ 9V δ 2 T cells of trafficking molecules and of molecules such as NKG2D that may contribute to tumor recognition (46, 47). The improved cell surface definition of an antitumor V γ 9V δ 2 T cell, coupled with the correlation of clinical outcome with the numbers of T_{EM} $\gamma\delta$ T cells, also suggests that in the short-term, the peripheral blood analysis of the status of $\gamma\delta$ cells, and of TRAIL, may provide a useful biomarker of a patient's antitumor response upon therapy with zoledronate + IL-2.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Grant support: Università di Palermo and Wellcome Trust, a grant from the Italian Association for Cancer Research (F. Dieli), and a Marie Curie grant (FP6; D. Vermijlen).

We thank Giorgio Stassi and Daniele Santini for reading the manuscript, Gavin Screaton for advice on TRAIL, Hassan Jomaa for help and advice, and Rong-Fu Wang for sharing data before manuscript submission

References

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. *CA Cancer J Clin.* 2005; 55:10–30. [PubMed: 15661684]
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. *J Urol.* 2004; 172:910–4. [PubMed: 15310996]
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. *J Urol.* 2003; 169:517–23. [PubMed: 12544300]
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA.* 1999; 281:1591–7. [PubMed: 10235151]
5. Bhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer—has there been real progress in the past decade? *Eur J Cancer.* 2005; 41:941–53. [PubMed: 15808960]
6. Diaz M, Patterson SG. Management of androgen-independent prostate cancer. *Cancer Control.* 2004; 11:364–73. [PubMed: 15625524]
7. McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. *Immunol Lett.* 2005; 96:3–9. [PubMed: 15585302]
8. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. *J Urol.* 2004; 172:2532–8. [PubMed: 15538202]
9. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. *Adv Immunol.* 2006; 90:1–50. [PubMed: 16730260]
10. Gattinoni L, Powell DJ Jr. Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. *Nat Rev Immunol.* 2006; 6:383–93. [PubMed: 16622476]
11. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by $\gamma\delta$ T cells. *Science.* 2001; 294:605–9. [PubMed: 11567106]
12. Belmant C, Decise D, Fournie JJ. Phosphoantigens and aminobisphosphonates: new leads targeting $\gamma\delta$ T lymphocytes for cancer immunotherapy. *Drug Discov Today.* 2006; 3:17–23.
13. Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD. Ex vivo expanded human V γ 9V δ 2+ $\gamma\delta$ -T cells mediate innate antitumor activity against human prostate cancer cells in vitro. *J Urol.* 2005; 173:1552–6. [PubMed: 15821484]

14. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V γ 9V δ 2 $\gamma\delta$ T cells in vitro and in SCID mice in vivo. *J Immunol.* 2004; 173:6767–76. [PubMed: 15557170]
15. Kunzmann V, Wilhelm M. Anti-lymphoma effect of $\gamma\delta$ T cells. *Leuk Lymphoma.* 2005; 46:671–80. [PubMed: 16019504]
16. Kabelitz D, Wesch D, He W. Perspectives of human $\gamma\delta$ T cells in tumor immunology. *Cancer Res.* 2007; 67:5–8. [PubMed: 17210676]
17. Morita CT, Mariuzza R, Brenner MB. Antigen recognition by human $\gamma\delta$ T cells: pattern recognition by the adaptive immune system. *Springer Semin Immunopathol.* 2000; 22:191–217. [PubMed: 11116953]
18. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human $\gamma\delta$ T cells by nonpeptidic mycobacterial ligands. *Science.* 1994; 264:267–70. [PubMed: 8146660]
19. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, Jomaa H. Microbial isoprenoid biosynthesis and human $\gamma\delta$ T cell activation. *FEBS Lett.* 2003; 544:4–10. [PubMed: 12782281]
20. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human $\gamma\delta$ T cells. *Nature.* 1995; 375:155–8. [PubMed: 7753173]
21. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor $\gamma\delta$ cells recognize endogenous mevalonate metabolites in tumor cells. *J Exp Med.* 2003; 197:163–8. [PubMed: 12538656]
22. Scotet E, Martinez LO, Grant E, et al. Tumor recognition following V γ 9V δ 2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. *Immunity.* 2005; 22:71–80. [PubMed: 15664160]
23. Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory V δ 2 T cells and migratory routes in lymph nodes or inflammatory sites. *J Exp Med.* 2003; 198:391–7. [PubMed: 12900516]
24. Wilhelm M, Kunzmann V, Eckstein S, et al. $\gamma\delta$ T cells for immune therapy of patients with lymphoid malignancies. *Blood.* 2003; 102:200–6. [PubMed: 12623838]
25. Dieli F, Gebbia N, Poccia F, et al. Induction of $\gamma\delta$ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. *Blood.* 2003; 102:2310–1. [PubMed: 12959943]
26. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using $\gamma\delta$ T cells against advanced renal cell carcinoma: a pilot study. *Cancer Immunol Immunother.* 2007; 56:469–76. [PubMed: 16850345]
27. Cannon GM Jr, Walsh PC, Partin AW, Pound CR. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. *Urology.* 2003; 62:2–8. [PubMed: 14747037]
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst.* 2000; 92:205–16. [PubMed: 10655437]
29. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. *J Clin Oncol.* 2003; 21:1404–11. [PubMed: 12663734]
30. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. *Support Care Cancer.* 2006; 14:408–18. [PubMed: 16450087]
31. Vermijlen D, Ellis P, Langford C, et al. Distinct cytokine-driven responses of activated blood $\gamma\delta$ T cells: insights into unconventional T cell pleiotropy. *J Immunol.* 2007; 178:4304–14. [PubMed: 17371987]
32. Wesch D, Glatzel A, Kabelitz D. Differentiation of resting human peripheral blood $\gamma\delta$ T cells toward Th1- or Th2-phenotype. *Cell Immunol.* 2001; 212:110–7. [PubMed: 11748927]
33. Eberl M, Engel R, Beck E, Jomaa H. Differentiation of human $\gamma\delta$ T cells towards distinct memory phenotypes. *Cell Immunol.* 2002; 218:1–6. [PubMed: 12470608]
34. Caccamo N, Meraviglia S, Ferlazzo V, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human V γ 9V δ 2 naive, memory and effector T cell subsets. *Eur J Immunol.* 2005; 35:1764–72. [PubMed: 15915537]

35. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. *Drugs*. 1993; 46:446–514. [PubMed: 7693434]
36. Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. *J Clin Oncol*. 1992; 10:33–40. [PubMed: 1727923]
37. Peest D, Leo R, Bloche S, et al. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. *Br J Haematol*. 1995; 89:328–37. [PubMed: 7873383]
38. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. *N Engl J Med*. 2005; 353:2654–66. [PubMed: 16371631]
39. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. *Immunol Cell Biol*. 2006; 84:87–98. [PubMed: 16405656]
40. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. *Nat Med*. 2005; 11:77–84. [PubMed: 15619633]
41. Bucur O, Ray S, Bucur MC, Almasan A. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. *Front Biosci*. 2006; 11:1549–68. [PubMed: 16368536]
42. Tateishi K, Ohta M, Guleng B, et al. TRAIL-induced cell death cooperates with IFN- γ activation in the graft-versus-tumor effect against colon tumors. *Int J Cancer*. 2006; 118:2237–46. [PubMed: 16331624]
43. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. *Nat Med*. 2006; 12:214–9. [PubMed: 16444265]
44. Chou AH, Tsai HF, Lin LL, Hsieh SL, Hsu PI, Hsu PN. Enhanced proliferation and increased IFN- γ production in T cells by signal transduced through TNF-related apoptosis inducing ligand. *J Immunol*. 2001; 167:1347–52. [PubMed: 11466352]
45. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. *Nat Med*. 2006; 12:693–8. [PubMed: 16680149]
46. Moris A, Rothenfusser S, Meuer E, Hangretinger R, Fisch P. Role of $\gamma\delta$ T cells in tumor immunity and their control by NK receptors. *Microbes Infect*. 1999; 1:227–34. [PubMed: 10801234]
47. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. *Nature*. 2001; 413:165–71. [PubMed: 11557981]

FIGURE 1.

$\gamma\delta$ T-cell numbers and activation markers in patients treated with zoledronate or zoledronate + IL-2. PBMC were obtained from patients treated with zoledronate alone (A) or with zoledronate + IL-2 (B), before starting treatment (*white columns*) and 3 mo (*gray columns*), 9 mo (*black columns*), and 12 mo (*hatched columns*) after treatment. Where no data are shown, patients had already died. PBMC were double stained with anti-CD3 and anti-V δ 2 mAbs and the absolute number of V γ 9V δ 2 T cells was calculated. The X-axis labeling indicates individual patients and their clinical status (P, progression; SD, stable disease; PR, partial remission). PBMC were stained with anti-CD3, anti-V δ 2, anti-CD69, and anti-HLA-DR mAbs. *Columns*, mean percentage of $\gamma\delta$ T cells expressing CD69 (C) and HLA-DR (D) molecules in patients treated with zoledronate alone (*empty columns*) or with zoledronate + IL-2 (*filled columns*); *bars*, SD.

FIGURE 2.

Distribution of $\gamma\delta$ T-cell subsets in patients treated with zoledronate + IL-2. PBMC were obtained from seven patients treated with zoledronate + IL-2, before starting treatment (month 0), and 3, 9, and 12 mo after treatment. After four-color staining of PBMC with anti-CD3, anti-V δ 2, anti-CD45RA, and anti-CD27 mAbs, the absolute number of V γ 9V δ 2 T_{naive} (CD45RA+CD27+), T_{CM} (CD45RA-CD27+), T_{EM} (CD45RA-CD27-), and T_{EMRA} (CD45RA+CD27-) cells was calculated. Top, bottom, and line through the middle of the boxes, 75th, 25th, and 50th percentiles. Lines that extend from the boxes, the highest and the lowest values from each subgroup. Lines within the boxes, median values.

FIGURE 3.

Proliferation, IFN- γ production, and cytotoxic activity of $\gamma\delta$ T cells in patients treated with zoledronate + IL-2. PBMC were obtained from seven patients treated with zoledronate + IL-2, before starting treatment (month 0), and 3, 9, and 12 mo after treatment. Cells were cultured *in vitro* with IPP and IL-2, as described in Materials and Methods. Proliferation was evaluated 7 d later, whereas IFN- γ production and BLT-esterase activities were assessed in the 48 and 24 h supernatants, respectively. *O.D.*, absorbance. *Points*, mean; *bars*, SD.

FIGURE 4.

A, Kaplan-Meier curves for 12-mo survival according to treatment with zoledronate (*dotted lines*) or zoledronate + IL-2 (*black-filled lines*). $P < 0.05$ by the log-rank, Breslow (generalized Wilcoxon) or Tarone-Ware tests. B, echo-color Doppler imaging of the prostate of patient 1B before (*top*) and 12 mo (*bottom*) after zoledronate + IL-2 therapy. *White arrow (top)*, an area of hypervascularization at the level of a hypoechoic nodule (*the darkest area surrounding the white dotted line*), which contains malignancy. Twelve months after therapy, the hypoechoic area is reduced and only one normal vessel is found in its context, indicating tumor regression. *Green box*, the area in which the echo-color Doppler signal was registered.

FIGURE 5.

Correlation between $\gamma\delta$ T-cell numbers and clinical outcome. A, numbers of total $\gamma\delta$ cells and (B) $V\delta 2+$ $\gamma\delta T_{EM}$ cells assessed at 9 mo after therapy are shown in three patients with partial remission, five patients with stable disease, and three patients with progression. •, patients treated with zoledronate + IL-2; Δ , patients treated with zoledronate alone. C, inverse correlation between numbers of total $\gamma\delta$ cells and (D) of $V\delta 2+$ $\gamma\delta T_{EM}$ cells and PSA levels, as assessed at 9 mo after therapy, in three patients with partial remission, five patients with stable disease, and three patients with progression (P). •, patients treated with zoledronate+IL-2; Δ , patients treated with zoledronate alone.

FIGURE 6.

Flow cytometry for intracellular TRAIL on cultured PBMC (A), influence of treatment (zoledronate $\pm$ IL-2) on serum TRAIL concentrations (B), and association between TRAIL concentrations and clinical outcome (C). A, percentage of V γ 9⁺CD3⁺ cells positive for TRAIL on day 3 ($n = 5$ healthy volunteers). Points, mean; bars, SE. B, TRAIL concentration in serum of patients treated with zoledronate only or zoledronate + IL-2, analyzed at indicated time points. See the legend to Fig. 2. C, TRAIL concentrations assessed at 9 mo after therapy are shown for three patients with partial remission, five patients with stable disease, and three patients with progression. Lines, median values.